Novel treatment options in the management of metastatic breast cancer.
Clinical Advances in Hematology and Oncology.
Times cited: 2
Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine.
Journal of Clinical Oncology.
Times cited: 153